Wolverine Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Wolverine Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,100	Closed	-$1.18M	–	2072
2022 Q4	$1.18M	Hold	9,100	–	–	0.01%	703
2022 Q3	$1M	Buy	+9,100	New	+$917K	0.01%	785
2021 Q1	–	Sell	-3,300	Closed	-$562K	–	2256
2020 Q4	$562K	Buy	+3,300	New	+$489K	﹤0.01%	811
2019 Q3	–	Sell	-6,100	Closed	-$926K	–	1614
2019 Q2	$926K	Hold	6,100	–	–	0.01%	690
2019 Q1	$727K	Buy	+6,100	New	+$784K	0.01%	752
2018 Q1	–	Sell	-10,000	Closed	-$556K	–	1659
2017 Q4	$556K	Sell	10,000 -3,200	-24%	-$170K	0.01%	878
2017 Q3	$598K	Buy	+13,200	New	+$528K	0.01%	794
2017 Q2	–	Sell	-41,100	Closed	-$1.22M	–	1442
2017 Q1	$1.22M	Buy	+41,100	New	+$1.27M	0.02%	488
2013 Q4	–	Sell	-21	Closed	-$5K	–	2920
2013 Q3	$5K	Buy	+21	New	+$809	﹤0.01%	2394

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Asset Management's SRPT Position: Q1 2026 in Review

Wolverine Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 65% in Q1 2026, selling an estimated $180K and leaving 4,920 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Wolverine Asset Management first reported a position in SRPT in Q4 2013 and has held it in 13 quarters since. The position peaked at $805K in Q1 2014. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Wolverine Asset Management held 4,920 shares of Sarepta Therapeutics worth $107K as of Q1 2026.
Wolverine Asset Management sold 9,317 Sarepta Therapeutics shares in Q1 2026, an estimated $180K.
Sarepta Therapeutics made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1169 holding.
Wolverine Asset Management first reported a position in Sarepta Therapeutics in Q4 2013 and has held it in 13 quarters since.
Wolverine Asset Management's Sarepta Therapeutics position peaked at $805K in Q1 2014.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.